Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.

ABSTRACT:

Background

Over 96% of high-grade ovarian carcinomas and 50% of all cancers are characterized by alterations in the p53 gene. Therapeutic strategies to restore and/or reactivate the p53 pathway have been challenging. By contrast, p63, which shares many of the downstream targets and functions of p53, is rarely mutated in cancer.

Methods

A novel strategy is presented for circumventing alterations in p53 by inducing the tumor-suppressor isoform TAp63 (transactivation domain of tumor protein p63) through its direct downstream target, microRNA-130b (miR-130b), which is epigenetically silenced and/or downregulated in chemoresistant ovarian cancer.

Results

Treatment with miR-130b resulted in: 1) decreased migration/invasion in HEYA8 cells (p53 wild-type) and disruption of mu

SUBMITTER: Gunaratne PH 

PROVIDER: S-EPMC6617807 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature